Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. [electronic resource] by
- Gaztanaga, Juan
- Farkouh, Michael
- Rudd, James H F
- Brotz, Tilmann M
- Rosenbaum, David
- Mani, Venkatesh
- Kerwin, Todd C
- Taub, Rebecca
- Tardif, Jean-Claude
- Tawakol, Ahmed
- Fayad, Zahi A
Producer: 20160105
In:
Atherosclerosis vol. 240
Availability: No items available.
|
|
7.
|
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. [electronic resource] by
- Tardif, Jean-Claude
- L'allier, Philippe L
- Ibrahim, Reda
- Grégoire, Jean C
- Nozza, Anna
- Cossette, Mariève
- Kouz, Simon
- Lavoie, Marc-André
- Paquin, Janie
- Brotz, Tilmann M
- Taub, Rebecca
- Pressacco, Josephine
Producer: 20100617
In:
Circulation. Cardiovascular imaging vol. 3
Availability: No items available.
|